Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review-Reference-Cited by-同舟云学术

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Published:2021-05-20 Issue:5 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Piechotta Vanessa¹,Iannizzi Claire²,Chai Khai Li³,Valk Sarah J⁴⁵,Kimber Catherine⁶,Dorando Elena¹,Monsef Ina¹,Wood Erica M³,Lamikanra Abigail A⁷,Roberts David J⁶,McQuilten Zoe³,So-Osman Cynthia⁸⁹,Estcourt Lise J¹⁰,Skoetz Nicole¹¹

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne; University of Cologne; Cologne Germany

3. Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

4. Jon J van Rood Center for Clinical Transfusion Research; Sanquin/Leiden University Medical Center; Leiden Netherlands

5. Department of Clinical Epidemiology; Leiden University Medical Center; Leiden Netherlands

6. Systematic Review Initiative; NHS Blood and Transplant; Oxford UK

7. Clinical, Research and Development; NHS Blood and Transplant; Oxford UK

8. Sanquin Blood Bank; Amsterdam Netherlands

9. Erasmus Medical Centre; Rotterdam Netherlands

10. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

11. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference449 articles.

1. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) (preprint) medRxiv 10.1101/2020.09.03.20187252

2. Convalescent plasma in the management of moderate Covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial);Agarwal;BMJ,2020

3. AlQahtani M Abdulrahman A Almadani A Alali SY Al Zamrooni AM Hejab A Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease (preprint) Medrxiv 2020 2020.11.02.20224303

4. Avendano-Sola C Ramos-Martinez A Munez-Rubio E Ruiz-Antoran B Malo de Molina R Torres F Convalescent plasma for COVID-19: a multicenter, randomized clinical trial (preprint) medRxiv 2020 2020.08.26.20182444 10.1101/2020.08.26.20182444

5. Diago-Sempere E Bueno JL Sancho-Lopez A Munez-Rubio E Torres F Malo de Molina R Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial Trials 2021 22 1 70

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dissemination of Registered COVID-19 Clinical Trials (DIRECCT): a cross-sectional study;BMC Medicine;2023-11-29

2. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial;BMJ Medicine;2023-10

3. COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy;Transplant Infectious Disease;2023-09-28

4. Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era;Experimental Hematology & Oncology;2023-07-27

5. Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy;Cells;2023-06-19